DIM on Euronext Paris

Sartorius Stedim Biotech

Logo: Sartorius AG, Public domain, via Wikimedia Commons3

Sartorius Stedim Biotech is a French supplier for biopharmaceutical company founded in 2007.1 Its website says: “As a leading partner of the biopharmaceutical industry, Sartorius Stedim Biotech helps its customers to develop their production processes and manufacture biotech medications and vaccines more efficiently. Sartorius Stedim Biotech is a globally operating company with subsidiaries in more than 30 countries and around 10,300 employees worldwide.”4 It is headquartered in Aubagne, France.1 It is part of Sartorius AG.1

Price unavailable

Last updated Oct 20, 2026.

Overview

2007Founded1

Compare with another stock.

See how the biggest companies compare on our leaderboards

Corporate structure

Sartorius Stedim Biotech is part of a group headed by Sartorius AG. 9 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Sartorius AG Göttingen, Germany
    • Sartorius Stedim Biotech 71.5% · Aubagne, France
      • Sartorius Stedim Biotech GmbH Subsidiary · Göttingen, Germany
    • SARTORIUS INDIA PRIVATE LIMITED Subsidiary · Bengaluru, India
    • Sartorius Lab Holding GmbH Subsidiary · Göttingen, Germany
    • Sartorius Lab Instruments GmbH & Co. KG Subsidiary · Göttingen, Germany
    • Sartorius Stedim FMT SAS Subsidiary · Aubagne, France
    • SARTORIUS STEDIM INDIA PRIVATE LIMITED Subsidiary · Bengaluru, India
    • Sartorius Weighing Technology GmbH Subsidiary · Göttingen, Germany

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

Subsidiaries and ownership

Parent company

From Wikidata.1

Timeline

  1. May 23, 2017Parent Directly consolidated by Sartorius AG2
  2. 2007Went public Listed on Euronext Paris1
  3. 2007Founded Founded1

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 48. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Mesirow Financial Investment Management, Inc.107,957$9.2M0.1%−620
Morgan Stanley32,139$2.7M0.0%+160
Smith, Moore & Co.31,594$2.7M0.2%No change
GHP Investment Advisors, Inc.30,975$2.6M0.1%−515
Wells Fargo & Company/mn26,104$2.2M0.0%+2,458
Bank Of America Corp /de/23,954$2.0M0.0%+29
Sanctuary Advisors, LLC23,751$2.0M0.0%+5,048
Rockefeller Capital Management L.P.22,039$1.9M0.0%−736
Cetera Investment Advisers15,329$1.3M0.0%−248
Susquehanna International Group, Llp14,473$1.2M0.0%+11,918
UBS Group AG14,278$1.2M0.0%−2,239
Geneos Wealth Management Inc.13,211$1.1M0.0%+45
Farther Finance Advisors, LLC11,102$946.2K0.0%+9,382
Envestnet Asset Management Inc8,823$752.0K0.0%−254
Royal Bank Of Canada8,342$711.0K0.0%+482
Jane Street Group, LLC8,124$692.4K0.0%−3,777
LPL Financial LLC6,159$524.9K0.0%+485
Osaic Holdings, Inc.5,103$434.9K0.0%+5,083
Invesco Ltd.4,829$411.6K0.0%−335
Cahill Financial Advisors Inc4,626$394.3K0.0%+191
Signature Estate & Investment Advisors LLC3,975$338.8K0.0%+75
Raymond James Financial Inc3,897$332.1K0.0%New
Assetmark, Inc3,755$320.0K0.0%New
Stifel Financial Corp3,662$312.1K0.0%+31
Cascade Financial Partners, LLC3,650$311.1K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4